Objective:

To assess medication satisfaction, quality-of-life improvements among Chinese patients with neuromyelitis optica spectrum disorder (NMOSD) treated with inebilizumab in real-world settings, and to provide evidence supporting clinical decision-making and patient-centered care.

Background:

NMOSD is a rare, relapsing, autoimmune inflammatory disorder of the central nervous system. Inebilizumab, a CD19-targeted monoclonal antibody, was approved in China in 2022 for adult AQP4-IgG-seropositive NMOSD patients. However, there remains a lack of systematic real-world evidence regarding its impact on patients’ quality of life.

Design/Methods:

A nationwide cross-sectional online survey was conducted between April and September 2025. Patients were recruited through NMOSD patient organization（DUOSHEN community）and voluntary sharing. Inclusion criteria were: (1) confirmed diagnosis of NMOSD; and (2) current or previous treatment with inebilizumab. The questionnaire encompassed demographic characteristics, disease history, treatment experience, quality of life, treatment satisfaction, and economic burden. All participants provided informed consent prior to enrollment. Data were anonymized to ensure privacy.

Results:

A total of 275 eligible NMOSD patients completed the survey (90.5% female; mean age 39.7 ± 11.8 years), with a mean treatment duration of 14.5 ± 8.4 months. Overall, 92.4% patients reported obvious symptomatic improvement following inebilizumab treatment, and 93.7% experienced reduced relapse rates. Quality of life(SF-36), showed marked improvement: 32% patients reported enhanced mental health, and 63% noted significant physical pain relief. Additionally, 32.4% patients reported returning to work. The average satisfaction score was 3.8 out of 5 and 96.7% expressed willingness to continue therapy. Noteworthy, a positive correlation was observed between inebilizumab duration time and patient satisfaction. Furthermore, 90.9% reported a reduced financial burden due to national health insurance coverage.

Conclusions:

Inebilizumab demonstrated high treatment satisfaction, significant relapse reduction, improved quality of life, and alleviated economic burden in Chinese NMOSD patients in real-world. It has emerged as a preferred treatment, facilitating long-term disease management and social reintegration.